Stay updated on Ravulizumab Study in LN/IgAN Clinical Trial
Sign up to get notified when there's something new on the Ravulizumab Study in LN/IgAN Clinical Trial page.

Latest updates to the Ravulizumab Study in LN/IgAN Clinical Trial page
- Check4 days agoChange DetectedA journal article analyzing urinary biomarkers from the SANCTUARY trial and their implications for IgA nephropathy and ravulizumab has been added to the study’s publications.SummaryDifference0.0%

- Check11 days agoChange DetectedThe ravulizumab trial record for lupus nephritis and IgA nephropathy is available, with study details and results information; it is marked terminated and no longer recruiting participants.SummaryDifference88%

- Check18 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0 on the page displaying a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide NIH notice was added above the page, announcing a transition in terminology from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer’s site revision changed from v3.7.0 to v3.7.1. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to Ravulizumab Study in LN/IgAN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ravulizumab Study in LN/IgAN Clinical Trial page.